University of Kentucky

UKnowledge
Pharmacy Practice and Science Faculty
Publications

Pharmacy Practice and Science

6-2016

National Trends in Off-Label Use of Atypical Antipsychotics in
Children and Adolescents in the United States
Minji Sohn
University of Kentucky, minjisohn@uky.edu

Daniela C. Moga
University of Kentucky, daniela.moga@uky.edu

Karen Blumenschein
University of Kentucky, kblum1@email.uky.edu

Jeffery C. Talbert
University of Kentucky, jeff.talbert@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/pps_facpub
Part of the Epidemiology Commons, Mental Disorders Commons, and the Pharmacy and
Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Sohn, Minji; Moga, Daniela C.; Blumenschein, Karen; and Talbert, Jeffery C., "National Trends in Off-Label
Use of Atypical Antipsychotics in Children and Adolescents in the United States" (2016). Pharmacy
Practice and Science Faculty Publications. 24.
https://uknowledge.uky.edu/pps_facpub/24

This Article is brought to you for free and open access by the Pharmacy Practice and Science at UKnowledge. It
has been accepted for inclusion in Pharmacy Practice and Science Faculty Publications by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

National Trends in Off-Label Use of Atypical Antipsychotics in Children and
Adolescents in the United States
Digital Object Identifier (DOI)
https://doi.org/10.1097/MD.0000000000003784

Notes/Citation Information
Published in Medicine, v. 95. issue 23, e3784, p. 1-7.
Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution-NonCommercialNoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any
medium, provided it is properly cited. The work cannot be changed in any way or used commercially.
http://creativecommons.org/licenses/by-nc-nd/4.0

This article is available at UKnowledge: https://uknowledge.uky.edu/pps_facpub/24

Medicine

®

Observational Study
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National trends in off-label use of atypical
antipsychotics in children and adolescents in the
United States
∗

Minji Sohn (PhD)a,c, , Daniela C. Moga (MD, PhD)a,b, Karen Blumenschein (PharmD, MS)a, Jeffery Talbert (PhD)a
Abstract
The objectives of the study were as follows: to examine the national trend of pediatric atypical antipsychotic (AAP) use in the United
States; to identify primary mental disorders associated with AAPs; to estimate the strength of independent associations between
patient/provider characteristics and AAP use. Data are from the National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey. First, average AAP prescription rates among 4 and 18-year-old patients between 1993 and 2010
were estimated. Second, data from 2007 to 2010 were combined and analyzed to identify primary mental disorders related to AAP
prescription. Third, a multivariate logistic regression model was developed having the presence of AAP prescription as the dependent
variable and patient/provider characteristics as explanatory variables. Adjusted odds ratios (AORs) with associated 95% conﬁdence
intervals (CIs) were estimated. Outpatient visits including an AAP prescription among 4 to 18-year-old patients signiﬁcantly increased
between 1993 and 2010 in the United States, and over 65% of those visits did not have diagnoses for US Food and Drug
Administration-approved AAP indications. During 2007 to 2010, the most common mental disorder was attention-deﬁcit
hyperactivity disorder, accounting for 24% of total pediatric AAP visits. Among visits with attention-deﬁcit hyperactivity disorder
diagnosis, those with Medicaid as payer (AOR 1.66, 95% CI 1.01–2.75), comorbid mental disorders (e.g., psychoses AOR 3.34, 95%
CI 1.35–8.26), and multiple prescriptions (4 or more prescriptions AOR 4.48, 95% CI 2.08–9.64) were more likely to have an AAP
prescription. The off-label use of AAPs in children and adolescents is prevalent in the United States. Our study raises questions about
the potential misuse of AAPs in the population.
Abbreviations: AAP = atypical antipsychotic, ADHD = attention-deﬁcit/hyperactivity disorder, AOR = adjusted odds ratios, CI =
conﬁdence interval, DSM = Diagnostic and Statistical Manual of Mental Disorders, FDA = Food and Drug Administration, ICD-9-CM
= International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, NAMCS = National Ambulatory Medical Care Survey,
NCHS = National Center for Health Statistics, NHAMCS = National Hospital Ambulatory Medical Care Survey.
Keywords: adolescents, attention-deﬁcit hyperactivity disorder, atypical antipsychotics, children, off-label

(also known as second-generation antipsychotics), which were
introduced during the 1990. Compared with the conventional
antipsychotics, AAPs were marketed as reducing adverse side
effects such as extrapyramidal symptoms. As a result, AAPs were
extensively used not only for the US Food and Drug
Administration (FDA)-approved indications but also for other
conditions not approved. Off-label use is controversial given the
uncertainty regarding the effectiveness and safety of AAPs.[2–5]
Several postmarketing clinical trials reported serious adverse side
effects, including metabolic syndrome, cardiovascular events, or
death in AAP users.[6–8] Nevertheless, AAPs are one of the topselling classes of pharmaceuticals in the United States. In fact,
antipsychotic medications generated about $18.2 billion total
revenue in 2011, with 3 individual AAP agents accounting for
65% of the total revenue.[9] In children and adolescents in the
United States, AAPs are probably among the most increasingly
used classes of prescription drugs.[10,11] A study by Patel et al[11]
reported that AAP use in children and adolescents increased 1.5
to 3-fold between 1996 and 2001 in Medicaid programs. Olfson
et al[12] reported a 5-fold increase during 1993 to 2002 in
antipsychotic prescription for young patients. However, to the
best of our knowledge, there are no studies to analyze the recent
trends in pediatric off-label AAP use and to evaluate the role of
patient and provider characteristics associated with it. Therefore,
this study was aimed to examine the historical trend of AAP use
among 4 to 18-year-old patients in the United States; to assess the
characteristics of AAP use by identifying primary mental

1. Introduction
Antipsychotic medications have long been used for the treatment
of mental disorders including psychosis, schizophrenia, and
bipolar disorder. These medications can be broadly categorized
into 2 classes: conventional antipsychotics, also known as ﬁrstgeneration antipsychotics or typical antipsychotics, which were
discovered in the 1950s[1]; and atypical antipsychotics (AAPs)
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identiﬁed using generic drug names as provided by the NCHS; for
after 2006, AAP use was identiﬁed based on Multum Lexincon
NAMCS/NHAMCS. Furthermore, AAP visits were categorized
into 2 groups based on the presence of one or more diagnosis
codes that corresponded to an US FDA-approved condition for
the prescription. During 1993 to 2010, AAPs were approved by
US FDA for the following 4 conditions: (1) schizophrenia (ICD-9CM, 295); (2) bipolar disorder (ICD-9-CM, 296.0; 296.1;
296.4–296.8); (3) depression (ICD-9-CM, 296.2; 296.3; 300.4;
311.X); and (4) autism (ICD-9-CM; 299.0). Figure 1 depicts US
FDA-approved indications for each AAP agent throughout
the study period. The US FDA approved olanzapine for
the manifestations of psychoses (ICD-9-CM; 290.XX-299.XX)
between 1996 and 2000. In 2000, the US FDA changed
the indication for olanzapine to schizophrenia and bipolar
disorder.

disorders; and to estimate the strength of independent association
of patient/provider characteristics with AAP prescription among
pediatric (4–18-year-old patients) attention-deﬁcit hyperactivity
disorder (ADHD) visits.

2. Materials and Methods
2.1. Data source
Data sources for this study were the National Ambulatory
Medical Care Survey (NAMCS) and the National Hospital
Ambulatory Medical Care Survey (NHAMCS). The NAMCS
and NHAMCS are national surveys that collect cross-sectional
data on outpatient visits to nonfederal employed, ofﬁce-based
physicians who are primarily engaged in direct patient care and
outpatient departments of noninstitutional general and shortstay hospitals. We intended to estimate the national trend of
nonemergent visits relevant to an AAP prescription. For this
reason, we excluded data collected from hospital emergency
departments and ambulatory surgery centers.
The NAMCS/NHAMCS data include patient sociodemographic characteristics, physician information, up to 3 diagnoses
relevant to the visit, and drugs prescribed. Diagnoses are recorded
using the “International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation” (ICD-9-CM). There were up
to 6 prescribed drugs recorded per visit during 1995 to 2002, and
up to 8 after 2003. To avoid overestimating the prescribing rate
and based on recommendations from the National Center for
Health Statistics (NCHS),[13] we only included the ﬁrst 6 drugs
listed per visit during our study period—1995 to 2010.
Data from 1993 to 2010 were used to compute the average
annual rate of pediatric AAP prescriptions. Data from 2007 to
2010 were used to identify primary mental disorders related to
AAP use and to estimate independent association of patient/
provider characteristics with AAP prescription among ADHD
visits. Sample weights to account for sampling techniques were
applied in all analyses using Stata statistical software (version
12). For this study, ethical approval was not necessary because it
used public use data sets.

2.3. National trend of AAP visit (1993–2010)
As the ﬁrst objective of the study, we examined the national trend
of AAP prescriptions by calculating average AAP visit rates
among 4 to 18-year-old patients for each survey year between
1993 and 2010. Based on signiﬁcant changes related to AAP use
that occurred during the study period, we combined survey years
and formed 3 phases. Speciﬁcally, each phase began when US
FDA approved an additional indication for AAP use: (1) phase I
between 1993 and 1999, (2) phase II between 2000 and 2002,
and (3)phase III between 2003 and 2010. For each phase, we
examined whether there were newly available AAP agents or
additional US FDA warnings.
2.4. Mental diagnoses related with AAP visit (2007–2010
combined)
As the second objective of the study, we identiﬁed primary mental
disorders related to AAP use. For each AAP visit, we examined (1)
whether any mental diagnosis (ICD-9-CM, 290.XX-310.XX)
was present, (2) whether the mental diagnosis was for an US
FDA-approved indication (as deﬁned above), and (3) what was
the ﬁrst-listed mental diagnosis for the visit. For mental health
visits without an US FDA-approved indication, the ﬁrst-listed
mental diagnosis was classiﬁed into following categories: (1)
psychoses with origin speciﬁc to childhood (“psychoses”
hereafter, ICD-9CM, 299.X); disturbances (ICD-9CM, 312.
XX; 313), (3) neurotic disorders (ICD-9CM, 300.0X; 300.1X,

2.2. Deﬁnition of an AAP visit
An outpatient visit was regarded as an AAP visit if one or more
following medications were prescribed: risperidone, olanzapine,
quetiapine, ziprasidone, aripiprazole, paliperidone, asenapine,
and iloperiodone. For the period 1993 to 2005, AAPs were

Figure 1. US FDA-approved indications for atypical antipsychotics. US FDA, US Food and Drug Administration.
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300.2X, 300.3; 300.5; 300.8X; 300.9), and (4) other mental
disorders (ICD-9-CM, other codes between 290.XX-310.XX).
2.5. Factors associated with an AAP prescription in
pediatric ADHD visits (2007–2010 combined)
As the third objective of the study, the strength of independent
association of patient/provider characteristics with AAP prescription among ADHD visits was estimated. Data from 2007 to
2010 were combined and analyzed to assess independent
associations of patient demographic/socioeconomic characteristics (age, sex, race, region of residence, household income/
education level based on ZIP code, and payer source), physician
characteristics (provider type, metropolitan statistical area
located), and patients’ health information (presence of hyperactivity, number of non-AAP drugs, other comorbidities) with an
AAP prescription among pediatric ADHD visits. A multivariate
logistic regression model was developed including these covariates, and adjusted odds ratios (AORs) with associated 95%
conﬁdence intervals (CIs) were estimated.
Among 4 to 18-year-old ADHD patient visits during 2007 to
2010, 4% had missing observations for variables that were based
on patient ZIP code, such as median household income and
percent of bachelor degree or higher. We did not include missing
observations in the analysis. However, we used imputed data for
observations missing a race variable. There were 29% missing
observations for the race variable, and we used NAMCS/
NHAMCS provided imputation values for those missing
observations. The method used by NAMCS/NHAMCS for
2007 and 2008 data to impute the race value was to use the
patient’s locality (ZIP code or state/county of residence),
physician locality, specialty, or 3-digit ICD-9-CM code for
primary diagnosis. If all failed to assign the race value, the
imputation was done based on a randomly selected record. For
2009 and 2010 data, race was imputed using a model-based,
single, sequential regression imputation method. The model for
imputing race is described in more detail in the 2009 to 2010
NAMCS/NHAMCS Public Use Data File Documentation.[14]

Figure 2. Atypical antipsychotic use in children and adolescents (age 4–18
years).

was 1.59 per 100 visits (95% CI 1.37–1.83), which is a
statistically signiﬁcant increase from phase II.
Throughout the study period, a majority of AAP visits did not
include a diagnosis for US FDA-approved indications (referred to
as “off-indication” in Fig. 2). The off-indication visits accounted
for approximately 86% of pediatric AAP visits during 1995 to
2003, and 71% during 2004 to 2010. A statistically signiﬁcant
increase for US FDA-approved AAP use was observed between
2003 and 2004 (P < 0.001) when the US FDA approved 3 AAP
agents (aripiprazole, quetiapine, and ziprasidone) for bipolar
disorder in addition to their previously approved indication,
schizophrenia.

3. Results
3.1. National trend of AAP prescription
From 1993 to 2010, the overall AAP use showed an increasing
pattern (Fig. 2). Starting from 1995, the rate of AAP prescription
increased gradually until 1999. Between 1999 and 2000, the
average AAP prescription rate doubled, increasing from 0.4 per
100 visits to 0.9 per 100 visits. A similar pattern occurred
between 2002 and 2003 when the average rate increased from 0.8
per 100 visits to 1.6 per 100 visits; after 2003, it showed a more
ﬂuctuating pattern.
It seems that the rates of AAP prescription increased
signiﬁcantly when the US FDA approved the drugs for
additional indications. During phase I (1993–1999), AAPs
were approved by the US FDA to treat schizophrenia; the
average AAP prescription rate for phase I was 0.15 per 100
visits (95% CI 0.1–0.21 per 100 visits). During phase II
(2000–2002), bipolar I disorder was added as a new indication
of AAPs; the average AAP prescription rate increased
signiﬁcantly to 0.81 per 100 visits (95% CI 0.54–1.21 per
100 visits). During phase III (2003–2010), the US FDA
approved AAPs for more indications, including depression
and autism. The average AAP prescription rate during phase III

3.2. Mental diagnoses related to AAP visit
The estimated number of total AAP visits for pediatric patients
during 2007 to 2010 was 8,380,436 (weighted count), which
accounted for approximately 2% of the total pediatric outpatient
visits in the United States. Of those, 34% included one or more
diagnoses of US FDA-approved indications (Fig. 3). Within this
group, a majority of visits had diagnoses of bipolar disorder or
depression (16% and 14% of total pediatric AAP visits,
respectively), followed by autism and schizophrenia (5% and
1% of total pediatric AAP visits, respectively). Approximately
2% of total pediatric AAP visits had 2 or more diagnoses of US
FDA-approved indications.
Among those without any US FDA-approved indications,
ADHD was the most common primary mental diagnosis (24% of
total pediatric AAP visits), followed by psychoses (14% of total
pediatric AAP visits). Disturbances and neurotic disorders took
up about 5% of total pediatric AAP visits, respectively.
Approximately 15% of total pediatric AAP visits did not include
any mental disorder diagnosis.
3
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between 1993 and 2010, and explored events related to AAPs.
Then, we identiﬁed mental diagnoses related to AAP prescription
for the period of 2007 to 2010. Lastly, we estimated the strength
of independent association of patient/provider characteristics
with AAP prescription among pediatric ADHD visits.
From 1993 and 2010, the overall AAP prescription rates in
pediatric outpatient visits showed an increasing pattern. There
was approximately 5-fold signiﬁcant increase from phase I
(1993–1999) to phase II (2000–2002), and 2-fold increase from
phase II to phase III (2003–2010). As more AAP agents became
available and the US FDA approved more indications, AAP
prescription rates increased (Fig. 2). Also, it seemed that sudden
increases in AAP prescription rates were associated with an US
FDA approval for an additional AAP indication. During 1993 to
2010, all AAP agents entered the market by obtaining US FDA
approval for the treatment of schizophrenia. Other indications
including bipolar disorder, depression, and autism were added to
the label a few years later. Interestingly, during the year of 2000
when bipolar disorder was ﬁrst indicated, there was an abrupt
increase in AAP prescription rates. Also, olanzapine was ﬁrst
approved for treatment of depression in 2003 and there was
another abrupt increase in AAP prescription rates. Autism was
added to the label of risperidone in 2006, and the rate increase
was the highest since 2003. However, it is difﬁcult to argue that
such increased prescription rates are mostly to treat the
additionally approved indication because the rate increased
not only for on-label but also for off-label. More speciﬁcally,
from phase I to phase II, AAP visits for US FDA-approved
indications increased only 0.09 per 100 pediatric outpatient
visits, whereas AAP visits for off-label uses increased 0.57 per 100
pediatric outpatient visits. Similarly, from phase II to phase III,
the magnitude of increase in off-label visits was larger than for US
FDA-approved indication visits (Fig. 2). Perhaps, having
approval for additional AAP indications impacted the AAP
therapy decision-making process in a way that AAPs were
regarded as useful for conditions other than currently approved
indications. Our analysis only intended to capture the national
trend, and further investigation using carefully designed models is
needed to clarify the association of a speciﬁc event with AAP
prescription rates.
Our analysis for identifying mental diagnoses that are related
to AAP prescriptions revealed that approximately 66% of total
pediatric AAP visits did not include a diagnosis for US FDAapproved indications. Of those, ADHD was the most common
primary mental diagnosis. This ﬁnding is consistent with several
previous studies that examined pediatric AAP use. Pathak et al[7]
assessed the dispensing pattern of AAPs using Arkansas Medicaid
claims data and reported ADHD as the most common condition
for children and adolescents to be prescribed AAPs. Cooper
et al[15] reported the same ﬁnding from the NAMCS/NHAMCS
data between 1995 and 2002. In the study, approximately 15%
of total pediatric AAP visits did not include any mental diagnosis.
In a study by Staller et al, 77% of the outpatient antipsychotic
visits did not include a mental diagnosis. They collected medical
and prescription data from 8 outpatient clinics in Central New
York in 2002. The fact that they had a much higher proportion of
psychiatric visits without a mental diagnosis than our study could
be explained by a number of factors, including different sampling
method, number of recorded diagnoses, or inclusion criteria in
deﬁning antipsychotic visits. Nonetheless, our study, with
previous studies, raises a major issue about current antipsychotic
prescription pattern in which antipsychotic medications could
frequently be misused in pediatric population.

Figure 3. Mental diagnoses related to AAP visits. AAP, atypical antipsychotic.

3.3. Factors associated with an AAP prescription in
pediatric ADHD visits
During 2007 to 2010, the total number of pediatric ADHD visits
was estimated to be 31,501,209 (weighted count). Of those, 12%
included 1 or more AAP prescriptions. Characteristics of
pediatric ADHD visits are summarized in Table 1. Patient
demographics and healthcare provider characteristics were not
statistically different between AAP visits and non-AAP visits. A
signiﬁcantly larger proportion of AAP visits had Medicaid as the
primary source of payment (52.50% vs 38.19%; P = 0.0135).
Regarding ADHD characteristics, AAP visits were more likely to
have attention-deﬁcit disorder with hyperactivity compared with
those without hyperactivity (58.76% vs 55.25%; P = 0.010).
More drugs (excluding AAPs) were prescribed during AAP visits
as compared with non-AAP visits. Comorbidity proﬁle was also
different in a way that AAP visits had more comorbid conditions
listed, including US FDA-approved AAP indications, psychoses,
neurotic disorder, disturbance, and diabetes.
In the multivariable logistic regression analysis, having
Medicaid as the primary payment source (AOR 1.66, 95%
CI 1.01–2.75), more non-AAP prescription medications (4 or
more prescriptions AOR 4.48, 95% CI 2.08–9.64), comorbid
mental disorders such as US FDA-approved AAP indications
(AOR 2.52, 95% CI 1.57–4.05), psychoses (AOR 3.34, 95% CI
1.35–8.26), neurotic disorder (AOR 2.67, 95% CI 1.27–5.61),
disturbance (AOR 3.60, 95% CI 1.94–6.69), and diabetes (AOR
14.21, 95% CI 1.77–114.28) signiﬁcantly increased the odds of
having an AAP prescription in a pediatric ADHD-related visit
(Table 2). However, having comorbid obesity was negatively
associated with an AAP prescription (AOR 0.03, 95% CI
0.01–0.19).

4. Discussion
The purpose of this study was to examine the national trend of
pediatric AAP use in an outpatient treatment setting in the United
States. We estimated the average annual AAP prescription rates
4
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Table 1
Characteristics of pediatric ADHD visits.
AAP visits (n = 3763)
Baseline characteristics

n

Non-AAP visits (n = 27,738)
%

n

Age
179
4.76
Preschool child (age 4–5)†
Elementary child (age 6–11)†
2026
53.84
Adolescent (age 12–18)†
1558
41.40
Sex
Male
2768
73.56
Female
995
26.44
Race
White
2948
78.34
Black
654
17.37
Other
162
4.30
Region of residence
Northeast
726
19.28
Midwest
896
23.82
South
1484
39.43
West
657
17.46
Median household income in patient’s zip code
Quartile 1
1086
28.85
Quartile 2
859
22.84
Quartile 3
792
21.05
Quartile 4
1026
27.26
Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1
1074
28.55
Quartile 2
859
27.22
Quartile 3
792
18.62
Quartile 4
1026
25.61
Metropolitan statistical area
No
487
12.93
Yes
3277
87.07
Payer source
Private
1533
40.75
Medicaid
1976
52.50
Self-pay
296
7.87
Other
1690
5.45
Mental health provider
No
1103
94.79
Yes
196
5.21
Attention deﬁcit disorder with hyperactivity
No
132
41.24
Yes
3632
58.76
Number of non-AAP prescribed (different generic names)
0
322
8.56
1
747
19.86
2
1058
28.11
3
836
22.22
4+
800
21.25
Comorbidities‡
US FDA-approved indications
970
25.77
Psychoses
321
8.53
Neurotic disorder
466
12.39
Adjustment disorder
88
2.33
Disturbance
886
23.55
Developmental disorder
177
4.70
Obesity
2
0.04
Diabetes
7
0.18
Cardiovascular disease
0
0.00

%

1213
17,081
9445

4.37
61.58
34.05

0.867
0.085
0.089

19,587
8151

70.62
29.38

0.498
0.498

22,427
4289
1021

80.85
15.46
3.68

0.449
0.507
0.744

4876
7160
11,011
4690

17.58
25.81
39.70
16.91

0.681
0.700
0.969
0.916

5886
8292
6106
7454

21.22
29.89
22.01
26.87

0.160
0.067
0.837
0.942

7648
8292
6106
7454

27.57
22.52
26.19
23.71

0.853
0.181
0.105
0.672

5542
22,195

19.98
80.02

0.248
0.248

14,726
10,593
1706
204

53.09
38.19
6.15
6.09

0.035
0.013
0.610
0.800

26,635
1103

96.02
3.98

0.341
0.341

4040
23,698

44.75
55.25

0.010
0.010

3417
13,180
5607
3152
2382

12.32
47.52
20.21
11.36
8.59

0.138
<0.001
0.007
0.001
<0.001

2304
547
1316
435
1769
799
371
4
10

8.31
1.97
4.75
1.57
6.38
2.88
1.34
0.01
0.04

<0.001
<0.001
0.001
0.304
<0.001
0.358
<0.001
0.008
0.611

AAP, atypical antipsychotic; ADHD, attention-deﬁcit hyperactivity disorder.

Data are given as weighted count of visits in thousands and percentage.
†
These variables were tested as binary variables. That is, instead of testing as a single age variable with three categories, the 3 categories were tested individually as binary variables.
‡
These variables are not mutually exclusive.
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From our logistic regression model estimating the association
between several factors and AAP prescription in ADHD
patients, patient demographics and healthcare provider
characteristics did not show a signiﬁcant relationship with
AAP prescription. Instead, patients’ medical proﬁles showed
much stronger associations with AAP prescription. More
speciﬁcally, having more coprescribed medications (i.e., other
than AAPs) and comorbid mental disorders, including US FDAapproved AAP indications, psychoses, neurotic disorder, and
disturbance, increased the likelihood of having an AAP
prescription. This result indicates that an AAP is more likely
to be prescribed to ADHD patients when multiple health
conditions are present. Medicaid being a signiﬁcant factor
could be explained with this result, because chronic illness and
other health risk factors are more prevalent among Medicaid
enrolees compared with those who are covered by private
insurance.[16–18]
Some limitations should be noted. First, the survey may not
capture sufﬁcient information to estimate the AAP prescription
rates and characteristics of visits. We used 6 ﬁrst-listed
medications and 3 diagnosis codes for the study period. Such
limited availability of medical/pharmacy records may have
misrepresented the true estimates in the study. For example, it
is possible that some AAP-treated patients had a severe physical
illness in addition to mental disorders, and due to the limited
space for the number of diagnosis codes on the survey form, their
healthcare providers were only able to record diagnoses for
physical illness. In this case, the visit data would have been
classiﬁed as an AAP visit with no mental disorder diagnosis code,
although the visit had a mental disorder diagnosis. Second, the
NAMCS/MHAMCS are designed to obtain the national/regional
estimate of outpatient healthcare service measures. State-level
estimates during the study period are unreliable, and we were
unable to assess the association of particular states with AAP
prescription rates. Third, due to the nature of micro visit level
data, the temporal relationship between explanatory variables
and AAP prescriptions was not identiﬁable. In other words, it is
not possible to conclude that having comorbid conditions
triggered the AAP use. Instead, we only observed that
comorbidities were associated with AAP use. Fourth, variables
of obesity, diabetes, and cardiovascular disease in our logistic
regression model had only a few observations, making the
estimated values unstable.
The ﬁndings of this study are from nonemergent outpatient
visits. Because our data source does not have hospital inpatient
data, we are apt to miss serious illness cases. This limitation could
lead to bias if hospitalized patients are exposed to AAPs at a rate
different from what is seen in the outpatient setting. For example,
we found that ADHD patients with another mental disorder
comorbidity were more likely to receive an AAP than those
without. Meanwhile, patients with comorbid mental disorders
such as schizophrenia or a mood disorder are more frequently
hospitalized,[19] indicating a possibility that hospitalized ADHD
patients may use AAPs more often than outpatient patients. Thus,
without inpatient visit data, our analysis would have underestimated the true association.
To minimize potential confounding, we reported AORs after
controlling for a number of mental and physical comorbidities.
However, our regression is limited to variables that are
observable and measurable from the data source. Also, we
grouped comorbid mental disorders into smaller categories, such
as US FDA-approved indications, to estimate the overall impact

Table 2
Factors associated with atypical antipsychotic prescription.
Covariates

Adjusted
odds ratio

95% Conﬁdence
interval

Age
Preschool child (age 4–5)
Reference
Elementary child (age 6–11)
0.86
0.35–2.09
Adolescent (age 12–18)
1.11
0.49–2.53
Sex
Male
Reference
Female
0.81
0.51–1.29
Race
White
Reference
Black
0.86
0.48–1.55
Others
2.05
0.77–5.43
Region of residence
Northeast
Reference
Midwest
0.84
0.40–1.75
West
0.84
0.38–1.84
South
0.90
0.43–1.89
Median household income in patient’s zip code
Quartile 1
Reference
Quartile 2
0.65
0.39–1.10
Quartile 3
0.79
0.38–1.65
Quartile 4
0.93
0.39–2.24
Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1
Reference
Quartile 2
1.31
0.73–2.33
Quartile 3
0.77
0.31–1.88
Quartile 4
1.02
0.41–2.50
Metropolitan statistical area
Yes
Reference
No
0.52
0.21–1.30
Payer source
Private
Reference
Medicaid
1.66‡
1.01–2.75
Self-pay
1.19
0.29–4.94
Other
1.08
0.38–3.09
Mental health provider
No
Reference
Yes
0.77
0.31–1.92
Attention deﬁcit disorder with hyperactivity
No
Reference
Yes
3.00
0.75–11.93
Number of non-AAP prescribed (different generic names)
0
Reference
1
0.94
0.58–1.52
2
2.60‡
1.38–4.90
1.48–6.32
3
3.06‡
4+
4.48‡
2.08–9.64
Mental comorbidities
US FDA-approved indications
2.52‡
1.57–4.05
1.35–8.26
Psychoses
3.34‡
Neurotic disorder
2.67‡
1.27–5.61
Adjustment disorder
1.21
0.57–2.58
Disturbance
3.60‡
1.94–6.69
Developmental disorder
1.81
0.71–4.63
Physical comorbidities†
Obesity
0.03
0.01–0.19
1.77–114.28
Diabetes
14.21‡
Cardiovascular disease
Dropped
US FDA, US Food and Drug Administration.

The variable of cardiovascular disease was dropped because it predicted no atypical antipsychotic
(AAP) use (AAP = 0) perfectly.
†
These variables are mutually exclusive.
‡
Signiﬁcant at 5% signiﬁcance level.
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antipsychotic medications for US children. Ambul Pediatr 2006;6:79–83.
[16] Rosenbaum S. Medicaid. N Engl J Med 2002;346:635–40.
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managed care. Pediatrics 1998;102:E44.
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Arch Pediatr Adolesc Med 2001;155:1161–7.
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of having those conditions, but we did not estimate the impact of
more speciﬁc disorders such as bipolar disorder or autism
spectrum disorder.
The identiﬁcation of mental disorders in this study was done
through ICD-9-CM, although “Diagnostic and Statistical
Manual of Mental Disorders” (DSM) serves as a more reliable
resource for prescribing clinicians in the United States. For
ADHD, ICD criteria seem to be more stringent than DSM
criteria, as ICD criteria do not recognize some subtypes
of ADHD.[20,21] As a result, the prevalence of ADHD would
be much lower for an ICD-based diagnosis than for DSMbased diagnosis.[22,23] Such discrepancies between ICD and DSM
relate to a potential misclassiﬁcation. In the absence of DSMbased diagnosis information, it is likely that the number of
ADHD cases from ICD-based records (reported as 24% of total
pediatric AAP visits) underestimates the number identiﬁed in
real practice.
Although our study covers the national trend until 2010,
several changes occurred in antipsychotic therapy and mental
disorder diagnosis during recent years. Several antipsychotic
agents were newly approved after 2010, and the introduction of
these agents would be expected to inﬂuence off-label antipsychotic use. Also, mental disorder diagnostic criteria were revised
in DSM-V, which was published in 2013. One of the changes
made in the DSM-V, unlike the previous version (DSM-IV), is
that ADHD can be diagnosed alongside autism spectrum
disorder. Previously, the presence of autism spectrum disorder
ruled out ADHD. This change may further inﬂate the rate of AAP
prescription in ADHD patients. Nonetheless, caution is required
in implementing the ﬁndings of this study, because it may not
represent the current trend. Further investigation of recent
changes in psychiatry and the impact on AAP use is an area for
further investigation.
In conclusion, we show that AAP prescription rates in 4 to 18year-old patients signiﬁcantly increased between 1993 and 2010
in the United States, and over 65% of those visits did not have a
diagnosis for US FDA-approved AAP indications. During 2007
to 2010, the most common mental disorder was ADHD,
accounting for 24% of total pediatric AAP visits. Among visits
with ADHD diagnosis, those with comorbid mental disorders
such as psychoses, neurotic disorder, and disturbance were more
likely to have an AAP prescription.
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